arrow
S

Satoshi Ikeda

Kansai Medical University Hospital
H指数:29
被引数:3,595

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of primary granulocyte colony-stimulating factor prophylaxis in patients with small-cell lung cancer receiving first-line platinum–etoposide plus a programmed death-ligand 1 inhibitor: A multicenter retrospective observational study

小细胞肺癌患者接受一线铂类–依托泊苷联合程序性死亡配体1抑制剂治疗时,初级粒细胞集落刺激因子预防的疗效与安全性:一项多中心回顾性观察性研究

2026-10-190
OA
Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer

日本乳腺癌和胃癌患者中曲妥珠单抗德鲁克替康相关间质性肺疾病的真实世界特征

2026-09-070
OAAI
Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab

利用数字设备数据开发不可切除III期非小细胞肺癌患者接受度伐利尤米治疗时发生间质性肺病的临床预测模型

2026-05-250
PRE
Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan

KRAS G12C突变型晚期非小细胞肺癌的临床轨迹:一项日本单中心队列研究

2026-05-010
PRE
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology

为什么选择Cemiplimab?在PD-L1表达超高水平且伴有鳞状组织学的非小细胞肺癌一线治疗中定义一个独特的治疗定位

Cancers
IF4.4
2026-01-170
OAAI
Targeting Driver Mutations in Lung Cancer with Interstitial Pneumonia: A Nationwide Study in Japan

靶向伴有间质性肺炎的肺癌驱动突变:一项日本全国性研究

2026-01-120
PRE
The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide

每周一次特立帕肽或每周两次特立帕肽给药后使用抗吸收剂的序贯疗法的影响

2026-01-012
OA
Concomitant Antiplatelet Therapy in Patients With Venous Thromboembolism Treated With Anticoagulants ― Insights From the COMMAND VTE Registry-2 ―

静脉血栓栓塞症接受抗凝治疗的患者中联合抗血小板治疗——COMMAND VTE 注册研究-2 的见解——

2025-09-010
OAAI
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)

度伐利尤单抗联合伊立替康+顺铂用于未经治疗的广泛期小细胞肺癌:REBORN,II期研究(WJOG13520L)

2025-06-290
OA
Initial anticoagulation therapy with single direct oral anticoagulant in patients with intermediate-high risk acute pulmonary embolism: From the COMMAND VTE Registry-2
2025-01-011
PRE
The efficacy of ICIs plus platinum-based chemotherapy for patients with advanced NSCLC and ECOG PS 2 (WJOG18424L): A propensity score-matched study

ICIs联合铂类化疗对ECOG PS 2评分的晚期NSCLC患者的疗效(WJOG18424L):一项倾向性评分匹配研究

2024-12-010
PRE
Clinical characteristics and short-term outcomes of patients with critical acute pulmonary embolism requiring extracorporeal membrane oxygenation: from the COMMAND VTE Registry-2
2024-11-050
OAAI
Incidence and risk factors of ischemic stroke in patients with cancer-associated venous thromboembolism: from the Contemporary Management and Outcomes in Patients With Venous Thromboembolism Registry-2
2024-11-010
OAAI
Impact of Implementation of a Region-Wide Low-Density Lipoprotein Cholesterol Management Clinical Pathway for the Secondary Prevention of Acute Myocardial Infarction
2024-10-253
OA
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
2024-04-133
OAAI
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis

尼达尼布联合化疗治疗小细胞肺癌合并特发性肺纤维化

2024-04-014
PRE